Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04564339 · ClinicalTrials.gov registry record · Phase 2
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
NCT04564339 is a Phase 2 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 123 participants.
The verdict
NCT04564339, a Phase 2 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety and efficacy of ravulizumab administered by intravenous (IV) infusion compared to placebo and demonstrate proof-of-concept of the efficacy of terminal complement inhibition in participants with LN (LN Cohort) or IgAN (IgAN Cohort).
Interventions
- DRUG Placebo
- DRUG Ravulizumab
- OTHER Background Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2021-01-19 |
| Est. Completion | 2025-08-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04564339
The ClinicalTrials.gov registry entry for NCT04564339 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04564339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04564339 about?
NCT04564339 is a clinical study titled "Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)". The objectives of this study are to evaluate the safety and efficacy of ravulizumab administered by intravenous (IV) infusion compared to placebo and demonstrate proof-of-concept of the efficacy of terminal complement inhibition in participants with LN (LN Cohort) or IgAN (IgAN Cohort).
What is the current status of trial NCT04564339?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2021-01-19. Estimated completion is 2025-08-18.
What interventions are being tested in trial NCT04564339?
The interventions under investigation include: Placebo (DRUG), Ravulizumab (DRUG), Background Therapy (OTHER).
Who is sponsoring clinical trial NCT04564339?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.